U.S. FDA and CMS Actions on Generative AI -Enabled Mental Health Devices Yield Insights ...
FDA continues to focus on a risk -based approach and a total product lifecycle approach (TPLC);; FDA is thinking critically about how clinical trial ...
Read the original at Key Areas of Impact for Life Sciences Companies ↗
- Topics
- HealthcareChatbots & LLMs
- Mentions
- FDAUnited States
- Tracked via
- “AI Risks”